Initiate Phase 2 triple combination study with Arbutus evaluating VBR, AB-729 and NrtI
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 25 Feb 2021
- Due
- 30 Jun 2021
- Delivered
- Q1 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Initiate Phase 2 triple combination study with Arbutus Biopharma Corporation evaluating VBR, RNAi therapeutic AB-729, and NrtI therapy in virologically-suppressed patients in H1 2021.”
What we found
Evidence strength A What the grades mean
The 10-K filed in March 2022 states the Phase 2 triple combination study initiated in Q1 2021, within the H1 2021 deadline.
-
A Assembly Biosciences, Inc. 10-K filed 2022-03-11
“This clinical study initiated in the first quarter of 2021 and completed enrollment in February 2022.” ✓ confirmed on the page
-
A Assembly Biosciences, Inc. 10-K filed 2022-03-11
“This clinical study initiated in the first quarter of 2021 and completed enrollment in February 2022.” ✓ confirmed on the page
Checked 26 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- Phase 2 triple combination study with Arbutus
- In the company’s control
- Medium
- Specificity
- High
- Depends on
- Partner
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Assembly Biosciences, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-ASMB-024644 · Corrections policy